Basal-like breast cancer: A review;Le cancer du sein de phénotype basal

Annales de Pathologie

Volumn 29, Issue 3, 2009, Pages 180-186

  Treilleux, Isabelle ^a   Morellon Mialhe, Blandine ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Basal cytokeratins; Basal phenotype; Breast cancer; Immunohistochemistry; Myoepithelial markers; Prognosis

Indexed keywords

CELL MARKER; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MEMBRANE PROTEIN; PROTEIN HER1; PROTEIN P63; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL FEATURE; HUMAN; IMMUNOHISTOCHEMISTRY; MYOEPITHELIUM; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY;

BREAST NEOPLASMS; FEMALE; HUMANS; KERATINS; MUSCLE PROTEINS; MYOEPITHELIOMA; NEOPLASM PROTEINS; PHENOTYPE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 67650474576     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2009.04.001     Document Type: Short Survey

References (37)

1. Soerjomataram I., Louwman M.W., Ribot J.G., Roukema J.A., and Coebergh J.W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107 (2008) 309-330
2. Perou C.M., Sorlie T., Eisen M.B., Van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
3. Collett K., Stefansson I.M., Eide J., Braaten A., Wang H., Eide G.E., et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14 (2005) 1108-1112
4. Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49 (2006) 22-34
5. Rakha E.A., Putti T.C., Abd El-Rehim D.M., Paish C., Green A.R., Powe D.G., et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208 (2006) 495-506
6. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12 (2006) 4185-4191
7. Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., and Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37 (2006) 1217-1226
8. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
9. Foulkes W.D., Stefansson I.M., Chappuis P.O., Bégin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (2003) 1482-1485
10. Laakso M., Loman N., Borg A., and Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18 (2005) 1321-1328
11. Fadare O., and Tavassoli F.A. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 14 (2007) 358-373
12. Fadare O., and Tavassoli F.A. Clinical and pathological aspects of basal-like breast cancers. Nat Clin Pract Oncol 5 (2008) 149-159
13. Banerjee S., Reis-Filho J.S., Ashley S., Steele D., Ashworth A., Lakhani S.R., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59 (2006) 729-735
14. Livasy C.A., Perou C.M., Karaca G., Cowan D.W., Maia D., Jackson S., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38 (2007) 197-204
15. Dabbs D.J., Chivukula M., Carter G., and Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 19 (2006) 1506-1511
16. Chu P.G., and Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology 40 (2002) 403-439
17. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
18. Reis-Filho J.S., Milanezi F., Carvalho S., Simpson P.T., Steele D., Savage K., et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 7 (2005) R1028-R1035
19. Birnbaum D., Bertucci F., Ginestier C., Tagett R., Jacquemier J., and Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminous?. Int J Oncol 25 (2004) 249-258 [review]
20. Lakhani S.R., Reis-Filho J.S., Fulford L., Penault-Llorca F., van der Vijver M., Parry S., et al. Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
21. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131 (2007) 18
22. Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T., Nesland J.M., et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 49 (2006) 10-21
23. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209 (2006) 445-453
24. Lambros M.B., Natrajan R., and Reis-Filho J.S. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 38 (2007) 1105-1122
25. Vincent-Salomon A., Gruel N., Lucchesi C., MacGrogan G., Dendale R., et al. Identification of typical medullary breast carcinoma as a genomic subgroup of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res Treat 9 (2007) 1-15
26. Rodriguez-Pinilla S.M., Sarrio D., Hondaro E., Moreno-Bueno G., Hardisson D., et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60 (2007) 1006-1012
27. Jacquemier J., Ginestier C., Rougemont J., Bardou V.J., Charafe-Jauffret E., Geneix J., et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65 (2005) 767-779
28. Jacquemier J., Padovani L., Rabayrol L., Lakhani S.R., Penault-Llorca F., Denoux Y., et al. Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207 (2005) 260-268
29. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
30. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37 (2000) 175-181
31. Bertucci F., Finetti P., Cervera N., Charafe-Jauffret E., Mamessier E., Adélaïde J., et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66 (2006) 4636-4644
32. Reis-Filho J.S., Milanezi F., Paredes J., Silva P., Pereira E.M., Maeda S.A., et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 11 (2003) 1-8
33. Fadare O., Wang S.A., and Hileeto D. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?. Hum Pathol 39 (2008) 331-336
34. Parikh R.R., Yang Q., Higgins S.A., and Haffty B.G. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys 70 (2008) 35-42
35. Tischkowitz M., Brunet J.S., Bégin L.R., Huntsman D.G., Cheang M.C., Akslen L.A., et al. Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancer 7 (2007) 134
36. Ihemelandu C.U., Naab T.J., Mezghebe H.M., Makambi K.H., Siram S.M., Leffall L.D., et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African-American women. Am J Surg 195 (2008) 153-158
37. Cheang M.C.U., Voduc D., Bajdik C., Leung S., Mc Kinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14 (2008) 1368-1376